NuVasive, Inc. (NUVA - Free Report) announced preliminary revenue results for the fourth quarter and 2019. The company is slated to release its detailed financial results for the same period in late February.
The preliminary figures for revenue growth rate for 2019 are higher than the company’s guidance and have surpassed the Zacks Consensus Estimate. However, this still fails to instill investors’ confidence, which is reflected through a 1.4% dip in the stock price that reached $79.61 on Jan 15 at the closing.
NuVasive expects total revenues of $310 million for the to-be-reported quarter, indicating 8% rise from the year-ago reported figure, on both reported and constant currency (CER) basis. Notably, the company’s guidance is above the Zacks Consensus Estimate of $304 million.
For the year, NuVasive's preliminary figures indicate a year-over-year improvement in total revenues to $1.17 billion, ahead of the company’s guidance of $1.14-$1.16 billion as well as the Zacks Consensus Estimate of $1.16 billion. This suggests 6% rise on a reported basis and a 7% increase at CER.
For 2019, strong uptick in total revenues is expected on robust growth in U.S. Spinal Hardware and international revenues. However, the company expects to witness marginal growth in U.S. Surgical Support revenues.
Preliminary figures for fourth-quarter indicate an expected revenue improvement for both U.S. Spinal Hardware and U.S. Surgical Support segments.
For the quarter, U.S. Spinal Hardware revenues are likely to rise 8% on a reported basis.
U.S. Surgical Support revenues are likely to rise 3% on a reported basis.
Geographically, the company’s international revenues are expected to increase 14% on both reported and CER basis.
Shares of NuVasive have gained 69.8% in the past year compared with the industry’s 14.6% growth.
Zacks Rank & Key Picks
Currently, the company carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , Hill-Rom Holdings, Inc. (HRC - Free Report) and Medtronic plc (MDT - Free Report) .
Haemonetics, currently flaunting a Zacks Rank #1 (Strong Buy), has a projected long-term earnings growth rate of 13.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hill-Rom’s long-term earnings growth rate is estimated at 11.7%. The company presently carries a Zacks Rank #2 (Buy).
Medtronic’s long-term earnings growth rate is estimated at 7.4%. It currently carries a Zacks Rank #2.
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our latest Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
See 5 Stocks Set to Double>>